What is Advanced non small cell lung cancer Treatment?
Created 3 weeks ago by anniepery

Erlotinib (Tarceva) is approved as an active inhibitor of the EGFR-TK. It inhibits the signal pathways existing in the cell proliferation and resists the growth as well as the spread of the tumor. Erlotinib 150 mg has been recommended by the NICE as a first-line treatment option for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR activating mutations. It has also been approved as an alternative to docetaxel as a second-line treatment for patients with NSCLC. Additionally, it is also approved in combination with another treatment named gemcitabine in case you've cancer of the pancreas at a metastatic stage. https://theindianpharmanetwork.tumblr.com/post/649521081189892096/history-of-erlotinib